FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and pharmacology, and concerns treating multiple sclerosis. There are presented: a pharmaceutical composition for mentioned application in children containing 0.25 mg and less of 2-amino-2-[2-(4-C2-C20alkylphenyl)ethyl]propane-1,3-diole or its pharmaceutically acceptable salt administered once a day; using the above compound (FTY720) in a dose of 0.25 mg or less for preparing a therapeutic agent for treating, preventing or delaying multiple sclerosis in the paediatric patients once a day, and a related method of treating, preventing or delaying multiple sclerosis in the paediatric patients.
EFFECT: treatment is effective and tolerated well by the adolescents.
15 cl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF S1P RECEPTOR AGONIST AND METHOD OF TREATMENT, ALLEVIATION OR RETARDATION OF OPTIC NEURITIS OR DEMYELINATING DISEASES PROGRESSION | 2003 |
|
RU2391094C2 |
ORGANIC COMPOUNDS | 2003 |
|
RU2478378C2 |
USING SIP RECEPTOR MODULATOR | 2008 |
|
RU2498796C2 |
ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
DOSING MODE OF S1P RECEPTOR MODULATOR | 2010 |
|
RU2776152C2 |
2-AMINO-1,3-PROPANEDIOL COMPOSITIONS | 2005 |
|
RU2402324C2 |
METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
LIQUID COMPOSITIONS | 2006 |
|
RU2428180C2 |
Authors
Dates
2015-09-10—Published
2009-06-19—Filed